Literature DB >> 11245209

Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading.

C Giannini1, B W Scheithauer, A L Weaver, P C Burger, J M Kros, S Mork, M B Graeber, S Bauserman, J C Buckner, J Burton, R Riepe, H D Tazelaar, A G Nascimento, T Crotty, G L Keeney, P Pernicone, H Altermatt.   

Abstract

Prognostic value of histological grading of oligodendroglial tumors is controversial and interobserver reproducibility in grading of these tumors is unknown. Seven neuropathologists and 6 surgical pathologists experienced in brain tumor-diagnosis assessed 124 oligodendroglial tumors operated at the Mayo Clinic (1960-1990). Among histologic parameters upon which current oligodendroglioma grading systems are based, only high cellularity, presence of mitoses, microcalcifications, endothelial hypertrophy, endothelial proliferation, and necrosis appeared to be reproducible. Reproducible histologic features, based on consensus ratings among neuropathologists (defined as > 60%), were evaluated for the association with cause-specific survival by fitting Cox regression models. By univariate analysis, a significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis. On multivariable analysis with a stepwise variable selection method, only age and presence of endothelial proliferation were found to be independently associated with survival with a discriminatory index of the model of 0.68. Mitotic index was significantly associated with survival based on the grading from each separate neuropathologist, but it was not based on consensus, most likely because this was classified as indeterminate in 54% of cases. Alternatively, "models fit" considering the assessment of single neuropathologists, identified a model based on age and on mitotic index with similar discriminatory indices of 0.69-0.7. Our study found few factors independently associated with cause specific-survival among morphological parameters. These findings are consistent with the present WHO stratification of oligodendrogliomas into low- and high-grade variants.

Entities:  

Mesh:

Year:  2001        PMID: 11245209     DOI: 10.1093/jnen/60.3.248

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  48 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.

Authors:  Sarah F Smith; Judy M Simpson; Janice A Brewer; Lali H S Sekhon; Michael T Biggs; Raymond J Cook; Nicholas S Little
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

3.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

4.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

5.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

6.  Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.

Authors:  Anna Latysheva; Kyrre Eeg Emblem; Petter Brandal; Einar Osland Vik-Mo; Jens Pahnke; Kjetil Røysland; John K Hald; Andrés Server
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

Review 7.  Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Authors:  Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

8.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

9.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

Review 10.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

Authors:  Martin J van den Bent
Journal:  Acta Neuropathol       Date:  2010-07-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.